These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 28872549)
1. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549 [TBL] [Abstract][Full Text] [Related]
2. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. Ulaner GA; Hyman DM; Ross DS; Corben A; Chandarlapaty S; Goldfarb S; McArthur H; Erinjeri JP; Solomon SB; Kolb H; Lyashchenko SK; Lewis JS; Carrasquillo JA J Nucl Med; 2016 Oct; 57(10):1523-1528. PubMed ID: 27151988 [TBL] [Abstract][Full Text] [Related]
3. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Ulaner GA; Carrasquillo JA; Riedl CC; Yeh R; Hatzoglou V; Ross DS; Jhaveri K; Chandarlapaty S; Hyman DM; Zeglis BM; Lyashchenko SK; Lewis JS Radiology; 2020 Aug; 296(2):370-378. PubMed ID: 32515679 [TBL] [Abstract][Full Text] [Related]
4. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695 [TBL] [Abstract][Full Text] [Related]
5. Bensch F; Brouwers AH; Lub-de Hooge MN; de Jong JR; van der Vegt B; Sleijfer S; de Vries EGE; Schröder CP Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2300-2306. PubMed ID: 30058029 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of [ Dehdashti F; Wu N; Bose R; Naughton MJ; Ma CX; Marquez-Nostra BV; Diebolder P; Mpoy C; Rogers BE; Lapi SE; Laforest R; Siegel BA Breast Cancer Res Treat; 2018 Jun; 169(3):523-530. PubMed ID: 29442264 [TBL] [Abstract][Full Text] [Related]
7. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Dijkers EC; Oude Munnink TH; Kosterink JG; Brouwers AH; Jager PL; de Jong JR; van Dongen GA; Schröder CP; Lub-de Hooge MN; de Vries EG Clin Pharmacol Ther; 2010 May; 87(5):586-92. PubMed ID: 20357763 [TBL] [Abstract][Full Text] [Related]
8. Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837 [TBL] [Abstract][Full Text] [Related]
9. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604 [TBL] [Abstract][Full Text] [Related]
10. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545 [TBL] [Abstract][Full Text] [Related]
11. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer. Eisses B; van Geel JJL; Brouwers AH; Bensch F; Elias SG; Kuip EJM; Jager A; van der Vegt B; Lub-de Hooge MN; Emmering J; Arens AIJ; Zwezerijnen GJC; Vugts DJ; Menke-van der Houven van Oordt CW; de Vries EGE; Schröder CP J Nucl Med; 2024 Oct; 65(10):1540-1547. PubMed ID: 39237347 [TBL] [Abstract][Full Text] [Related]
12. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with McKnight BN; Viola-Villegas NT Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299 [TBL] [Abstract][Full Text] [Related]
13. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Gaykema SB; Schröder CP; Vitfell-Rasmussen J; Chua S; Oude Munnink TH; Brouwers AH; Bongaerts AH; Akimov M; Fernandez-Ibarra C; Lub-de Hooge MN; de Vries EG; Swanton C; Banerji U Clin Cancer Res; 2014 Aug; 20(15):3945-54. PubMed ID: 25085789 [TBL] [Abstract][Full Text] [Related]
14. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. Tamura K; Kurihara H; Yonemori K; Tsuda H; Suzuki J; Kono Y; Honda N; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Hasegawa K; Kanayama Y; Nozaki S; Kinoshita T; Wada Y; Tazawa S; Takahashi K; Watanabe Y; Fujiwara Y J Nucl Med; 2013 Nov; 54(11):1869-75. PubMed ID: 24029656 [TBL] [Abstract][Full Text] [Related]
17. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer. Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821 [TBL] [Abstract][Full Text] [Related]
18. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. Sandberg D; Tolmachev V; Velikyan I; Olofsson H; Wennborg A; Feldwisch J; Carlsson J; Lindman H; Sörensen J Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1337-1346. PubMed ID: 28261749 [TBL] [Abstract][Full Text] [Related]
19. Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study. Tőkés T; Szentmártoni G; Torgyík L; Kajáry K; Lengyel Z; Györke T; Molnár BÁ; Tőkés AM; Kulka J; Dank M Croat Med J; 2015 Apr; 56(2):128-38. PubMed ID: 25891872 [TBL] [Abstract][Full Text] [Related]
20. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]